A5032880179- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- RNA Interference and Gene Delivery
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Virus-based gene therapy research
- MicroRNA in disease regulation
- Immunotherapy and Immune Responses
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Mass Spectrometry Techniques and Applications
- Japanese History and Culture
- Advanced biosensing and bioanalysis techniques
- Immune Cell Function and Interaction
- Hematological disorders and diagnostics
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Medical Imaging Techniques and Applications
- CRISPR and Genetic Engineering
- T-cell and B-cell Immunology
- Cancer, Lipids, and Metabolism
Medizinische Hochschule Hannover
2016-2025
German Cancer Research Center
2014-2024
Heidelberg University
2014-2024
University Medical Center Freiburg
2017-2024
University of Freiburg
2017-2024
Graz University of Technology
2024
Deutschen Konsortium für Translationale Krebsforschung
2014-2024
Leibniz Institute for Immunotherapy
2024
Klinik und Poliklinik für Nuklearmedizin
2023
University of Music and Performing Arts Vienna
2022
Since the introduction of positron emission tomography (PET) imaging with 68Ga-PSMA-HBED-CC (=68Ga-DKFZ-PSMA-11), this method has been regarded as a significant step forward in diagnosis recurrent prostate cancer (PCa). However, published data exist for small patient cohorts only. The aim evaluation was to analyse diagnostic value 68Ga-PSMA-ligand PET/CT large cohort and influence several possibly interacting variables. We performed retrospective analysis 319 patients who underwent from 2011...
Positron emission tomography (PET) with choline tracers has found widespread use for the diagnosis of prostate cancer (PC). However, metabolism is not increased in a considerable number cases, whereas prostate-specific membrane antigen (PSMA) overexpressed most PCs. Therefore, (68)Ga-labelled PSMA ligand could be superior to by obtaining high contrast. The aim this study was compare such novel tracer standard choline-based PET/CT.Thirty-seven patients biochemical relapse PC [mean (PSA) 11.1...
Urea-based inhibitors of the prostate-specific membrane antigen (PSMA) represent low-molecular-weight pepidomimetics showing ability to image PSMA-expressing prostate tumors. The highly efficient, acyclic Ga(III) chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'- diacetic acid (HBED-CC) was introduced as a lipophilic side chain into hydrophilic pharmacophore Glu-NH-CO-NH-Lys which found favorable interact with PSMA "active binding site". This report describes...
Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake, making it choice therapeutic application. We retrospectively report our experience with <sup>177</sup>Lu-PSMA-617–targeted in a case series mCRPC patients resistant to other treatments. <b>Methods:</b> Patients PSMA-positive phenotypes...
Despite many advances in the past years, treatment of metastatic prostate cancer still remains challenging. In recent prostate-specific membrane antigen (PSMA) inhibitors were intensively studied to develop low-molecular-weight ligands for imaging lesions by PET or SPECT. However, endoradiotherapeutic use these compounds requires optimization with regard radionuclide-chelating agent and linker moiety between chelator pharmacophore, which influence overall pharmacokinetic properties resulting...
The high-affinity receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) consists of a unique alpha chain and beta c subunit that is shared with the receptors interleukin-3 (IL-3) IL-5. Two regions have been defined; these include membrane-proximal region cytoplasmic domain required mitogenesis membrane-distal activation Ras, Raf-1, mitogen-activated protein kinase, S6 kinase. Recent studies implicated tyrosine kinase JAK2 in signalling through number cytokine receptors,...
Abstract Purpose Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in diagnosis recurrent prostate cancer (PCa). The aim study was to analyse influence several variables with possible on PSMA ligand uptake large cohort. Methods We performed retrospective analysis 1007 consecutive patients who were scanned PET/CT (1 h after injection) from January 2014 2017 detect disease. Patients untreated...
PET imaging with the prostate-specific membrane antigen (PSMA)–targeted radioligand <sup>68</sup>Ga-PSMA-11 is regarded as a significant step forward in diagnosis of prostate cancer (PCa). More recently, PSMA ligand was developed that can be labeled <sup>68</sup>Ga, <sup>111</sup>In, <sup>177</sup>Lu, and <sup>90</sup>Y. This ligand, named PSMA-617, therefore enables both therapy PCa. The aims this evaluation were to clinically investigate distribution <sup>68</sup>Ga-PSMA-617 normal tissues...
The detection of prostate cancer lesions by PET imaging the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which recently demonstrated its suitability in individual first-in-man studies. radiometal chelator HBED-CC used this molecule rather rarely acyclic complexing agent with chemical characteristics favourably influencing...
Purpose Reduced intensity conditioning regimen (RIC) is increasingly used in hematopoietic stem cell transplantation (HSCT). Unrelated donor (UD) transplants have more complications. We wanted to examine if RIC a valid treatment option using UD acute myeloblastic leukemia (AML). Patients and Methods Between 1999 2005, 401 patients with AML were treated 1,154 received myeloablative (MAC), reported the European Group for Blood Marrow Transplantation Registry. < ≥ 50 years of age analyzed...
In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them had a high clinical impact on treatment patients with prostate cancer. However, number <sup>18</sup>F-labeled tracers addressing PSMA is still limited. Therefore, we aimed to develop radiofluorinated molecule resembling structure therapeutic PSMA-617. <b>Methods:</b> The nonradioactive reference compound PSMA-1007 and precursor were produced by solid-phase...
Since prostate-specific membrane antigen (PSMA) is up-regulated in nearly all stages of prostate cancer (PCa), PSMA can be considered as a viable diagnostic biomarker and treatment target PCa. This project focused on the development evaluation series compounds directed against PSMA. The modifications to linker are designed improve binding potential pharmacokinetics for theranostic application. In addition, results help further elucidate structure-activity relationships (SAR) resulting...